1. GATA3 as an immunomodulator in obesity-related metabolic dysfunction associated with fatty liver disease, insulin resistance, and type 2 diabetes.
- Author
-
El-Arabey, Amr Ahmed and Abdalla, Mohnad
- Subjects
- *
METABOLIC disorders , *FATTY liver , *TYPE 2 diabetes , *ADIPOSE tissues , *INSULIN resistance , *EMBRYONIC stem cells , *ADIPOGENESIS - Abstract
Obesity is the leading risk factor associated with Metabolic dysfunction Associated with Fatty Liver Disease (MAFLD), Insulin Resistance (IR), and type 2 diabetes (T2DM). Notably, MAFLD affects 25% of the world's adult population, ranging from 13.5% in Africa to 31.8% in the Middle East. The prevalence of MAFLD is 80–90% in obese adults and 30–50% in patients with diabetes. According to the recent WHO update, more than 400 million people will experience T2DM by 2025. Furthermore, the worldwide obesity incidence rate has risen in the preceding years. Adipogenesis deterioration is a critical step in the induction of obesity correlated with MAFLD, IR and T2DM. The well-known transcription factor GATA3 is highly expressed in the preadipocytes-adipocytes transition of embryonic stem cells and obese people with IR. In this regard, the reduction of GATA3 improves the differentiation of adipocytes. Omental adipose tissue inflammation by upregulation of macrophages infiltration is strongly linked with body mass index in insulin tolerance of obese people. In particular, the dynamic interaction between macrophages and adipocytes significantly regulates obese adipose tissue's inflammatory status and influences IR by reducing the differentiation of adipocytes, macrophage function, and glucose transport. Emerging evidence demonstrated that GATA3 is a master regulator for macrophage polarization and infiltration. Hence, we will shed light on GATA3 as an emerging target for immunomodulation in human obesity associated with MAFLD, IR, and T2DM by reducing macrophages' recruitment and inflammation of muscles and liver. • The omental expression of GATA3 in obese people induces MAFLD, IR and T2DM. • GATA3 is an immunomodulator in obese people associated with MAFLD, IR and T2DM. • GATA3 induces predominant M1 macrophages in obese people associated with MAFLD. • GATA3-induces liver and muscle inflammation and ATMs invasion in obese people. • GATA3 is a promising target in obesity-related MAFLD, IR, and T2DM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF